CCI approves proposed merger between Sun Pharma and Ranbaxy
The Competition Commission of India (Commission) in its meeting approved the proposed merger between Sun Pharma and Ranbaxy, subject to the parties inter alia carrying out the divestiture of their products relating to seven relevant markets for formulations. Further, the Commission also directed that the proposed merger shall not take effect before the parties have carried-out the divestiture of the products so specified as per the order of the Commission.
Earlier on 6th May, 2014(06.05.2014), the Commission had received a notice from Sun Pharmaceuticals Industries Limited (Sun Pharma) and Ranbaxy Laboratories Limited (Ranbaxy) in relation to the merger of Ranbaxy into Sun Pharma.
On the basis of combined market share of the parties, incremental market share as a result of the proposed combination, market share of the competitors, number of significant players in the relevant market etc., the Commission focussed its investigation on some relevant markets for formulations where the proposed combination was likely to have an appreciable adverse effect on competition in the relevant market in India.
Cipla unit to sell stake in Jiangsu Cdymax for $18.5 mn
Cipla Ltd has informed BSE that Meditab Holdings Limited, Mauritius, a wholly owned subsidiary of the Company, has entered into a definitive agreement to sell its entire 48.22% equity interest in Jiangsu Cdymax Pharmaceuticals Co. Ltd., China (Jiangsu) to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of USD 18.5 million. The closing of the transaction is subject to receipt of applicable regulatory approvals in China.
COOs say advanced operating models can positively impact strategic challenges: Survey
Genpact Limited, a global leader in designing, transforming, and running intelligent business process operations, has released the healthcare industry findings excerpted from its survey of 920 senior executives. These insights come from operations leaders at healthcare payer organizations in North America –predominantly large companies with more than 10,000 employees.
This global study reveals how senior leaders across industries are prioritizing key operational initiatives to materially address the critical challenges that their companies face. While 66% of the healthcare executives surveyed see regulatory compliance as a top challenge in an environment of healthcare reform and increased government scrutiny, consumer satisfaction and cost reduction are also among the top enterprise challenges that healthcare COOs must tackle.
More than 98% of babies born in India are exposed to risk of Congenital Hypothyroidism: ICMR
In a recently released study by Indian Council of Medical Research (ICMR), Congenital Hypothyroidism affects 1 in 1172 newborn babies in India. This figure is highly alarming when compared to worldwide statistics of 1 in 3,800 newborn babies. In such a situation, it is extremely essential to screen newborns to ensure early detection & diagnosis of the disease. Trivitron Healthcare, India’s largest Medical Technology Company, pioneers the most cost effective 'Newborn Screening' tests in India.
'Congenital Hypothyroidism' is a condition in newborn babies that is caused due to the deficiency of thyroid hormones. In newborn babies, thyroid hormones are extremely important for brain development and overall growth.
Lupin launches Authorized Generic for Celebrex Capsules
Pharma Major Lupin Limited announced that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the authorized generic for G.D. Searle LL C’s (a subsidiary of Pfizer Inc.) Celebrex Capsules (Cele brex) 50 mg, 100 mg, 200 mg and 400 mg strengths. Lupin had earlier signed a licensing agreement with Pfizer Inc. regarding Celebrex. Celebrex Capsules had annual U.S sales of US$ 2.54 billion (IMS MAT September, 2014).
Germany bans 80 generic drugs for insufficient trials by GVK
Germany's drug regulator has banned sale of 80 generic medicines with immediate effect on the grounds that their clinical trials conducted by GVK Biosciences were "insufficient", says report. The regulator reported that it did not expect its ban to cause any shortage of supplies.
Ranbaxy Laboratories clarifies reports
The Exchange had sought clarification with respect to the following statement of Ranbaxy Laboratories Ltd on December 8, 2014. "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws.
Ranbaxy is pleased with this verdict, and is committed to serving patients, prescribers and the US healthcare system."
ProSport Fitness in collaboration with CODS bequeaths nutritional support for holistic living
Prosport Fitness & Sports in Lower Parel, is the state of the art 4500sft ProSport center designed and equipped with the finest systems has collaborated with CODS to identify strategies, to advance awareness and promotion of physical activity, fitness, and nutrition throughout the entire life span, especially targeted to all age groups from kids, teenagers, adults to the elderly.
CODS (Center of Obesity and Digestive Surgery) is founded by the renowned Bariatric Surgeon Dr. Muffazal Lakdawala who has been at the forefront of Obesity Management via surgical and non-surgical methods across India and strives to increase awareness about obesity and its co-morbidities. The collaboration with ProSport Fitness solidifies their expanding focus that recognizes the need for people of all ages to remain active, which can help improve quality of life, facilitate enhanced lifestyle management, reduce the instance of chronic disease. The aim of this program is to endow innovative ways and help people from all age groups with holistic living.
Zydus launches world’s first biosimilar of Adalimumab
Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab – the world’s largest selling therapy. Developed by the researchers at the Zydus Research Centre, the biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name, Exemptia to treat auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.
This novel non-infringing process for Adalimumab and a novel non-infringing formulation has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a ‘fingerprint match’ with the originator in terms of safety, purity and potency of the product. The biosimilar of Adalimumab is a part of Zydus’ robust biologics programme which has the largest number of monoclonal antibodies under development in India. The group’s R&D pipeline which comprises 24 biologics includes biosimilars and three novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.
Dr. Habil Khorakiwala appointed Chancellor of Jamia Hamdard University
Jamia Hamdard University has appointed Dr. Habil Khorakiwala as its new Chancellor. Dr. Habil Khorakiwala will occupy the esteemed position for a period of 5 years beginning December 2014. Dr. Habil Khorakiwala is the Chairman of Wockhardt Group, India’s leading healthcare conglomerate with presence across Pharmaceuticals, Biotechnology, and Super Speciality Hospitals.
Talking on the appointment, Dr. Habil Khorakiwala, said, “I intend to create a vision for the Jamia Hamdard University - to be at the forefront of imparting right education and knowledge in the 21st century.”
Dr. G. N. Qazi, Vice Chancellor, Jamia Hamdard University, said, “We are indeed happy that Dr. Habil Khorakiwala has accepted to be the Chancellor of our University. With his established leadership and interest in science and technology, the University would benefit from his direction and guidance.”
Merck to buy Cubist Pharma
Merck & Co Inc is reportedly in talks to acquire Cubist Pharmaceuticals Inc for more than $7 bn. The deal that may be announced this week.Merck will likely pay roughly $100 a share for Cubist, says report. Cubist reported 16% jump in third-quarter sales in October.